Pfizer to Buy Metsera and its Modern Obesity Portfolio

Pfizer, a renowned biopharmaceutical company, recently announced its definitive agreement to acquire Metsera, Inc., a clinical-stage biopharmaceutical company specializing in the development of cutting-edge medications for obesity and related cardiometabolic diseases. This strategic acquisition marks Pfizer’s foray into the rapidly expanding realm of obesity therapeutics, aligning with the company’s commitment to investing in high-impact areas to address critical unmet needs in healthcare. With the unanimous approval of both companies’ Boards of Directors, this merger is poised to usher in a new era of innovation and advancement in the treatment of obesity.

Obesity represents a pervasive health concern worldwide, with a myriad of associated conditions impacting individuals’ well-being. By acquiring Metsera, Pfizer aims to bring its extensive experience in cardiometabolic disorders and its robust manufacturing and commercial infrastructure to bolster Metsera’s portfolio of innovative oral and injectable therapeutic candidates. These candidates, encompassing incretin, non-incretin, and combination therapies, are designed to offer superior efficacy and safety profiles, potentially setting new standards in the treatment of obesity and related disorders.

Metsera’s pipeline comprises a diverse range of promising therapeutic candidates and combination therapies, including the groundbreaking MET-097i, a weekly and monthly injectable GLP-1 receptor agonist currently in Phase 2 development. Additionally, MET-233i, a monthly amylin analog candidate under evaluation as a monotherapy and in combination with MET-097i in Phase 1 trials, showcases the company’s commitment to revolutionary treatment modalities. With two oral GLP-1 RA candidates on the horizon and ongoing preclinical studies on nutrient-stimulated hormone therapeutics, Metsera is spearheading a wave of innovation in the field of metabolic disorders.

Under the terms of the agreement, Pfizer will acquire all outstanding shares of Metsera’s common stock for $47.50 per share in cash, representing an initial enterprise value of approximately $4.9 billion. Moreover, shareholders are entitled to contingent value rights (CVR) that offer additional cash payments of up to $22.50 per share tied to specific clinical and regulatory milestones, underscoring the shared commitment to advancing transformative therapies in the obesity space. This transaction is projected to finalize in the fourth quarter of 2025, pending customary closing conditions and regulatory approvals.

Whit Bernard, Co-Founder and CEO of Metsera, expressed enthusiasm for the partnership, emphasizing the potential impact on millions of individuals grappling with the challenges of obesity and related conditions. By harnessing Pfizer’s global resources and expertise across clinical, regulatory, manufacturing, and commercial domains, Metsera’s groundbreaking therapeutics are poised to reach a broader audience and effect transformative change on a massive scale.

The acquisition of Metsera signifies Pfizer’s strategic vision to expand its footprint in the obesity therapeutics market and underscores its unwavering commitment to addressing critical healthcare needs. With a shared dedication to innovation and excellence, Pfizer and Metsera are poised to chart new territories in the treatment of obesity, offering hope and improved outcomes to individuals worldwide.